Vivos Therapeutics Stock Revenue
| VVOS Stock | USD 4.52 0.06 1.35% |
Fundamental analysis of Vivos Therapeutics allows traders to better anticipate movements in Vivos Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 15 M | 14.1 M |
Vivos | Revenue | Build AI portfolio with Vivos Stock |
Vivos Therapeutics Company Revenue Analysis
Vivos Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Vivos Therapeutics Revenue | 15.03 M |
Most of Vivos Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Vivos Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Vivos
Projected quarterly revenue analysis of Vivos Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Vivos Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Vivos Therapeutics' stock price.
Vivos Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Vivos Therapeutics is extremely important. It helps to project a fair market value of Vivos Stock properly, considering its historical fundamentals such as Revenue. Since Vivos Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vivos Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vivos Therapeutics' interrelated accounts and indicators.
| 0.78 | 0.59 | -0.82 | 0.83 | 0.72 | ||
| 0.78 | 0.92 | -0.93 | 0.43 | 0.89 | ||
| 0.59 | 0.92 | -0.84 | 0.2 | 0.76 | ||
| -0.82 | -0.93 | -0.84 | -0.44 | -0.96 | ||
| 0.83 | 0.43 | 0.2 | -0.44 | 0.35 | ||
| 0.72 | 0.89 | 0.76 | -0.96 | 0.35 |
Click cells to compare fundamentals
Vivos Revenue Historical Pattern
Today, most investors in Vivos Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vivos Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Vivos Therapeutics revenue as a starting point in their analysis.
Vivos Therapeutics Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Vivos Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Vivos Therapeutics reported 15.03 M of revenue. This is 99.8% lower than that of the Health Care Equipment & Supplies sector and 99.41% lower than that of the Health Care industry. The revenue for all United States stocks is 99.84% higher than that of the company.
Vivos Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vivos Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vivos Therapeutics could also be used in its relative valuation, which is a method of valuing Vivos Therapeutics by comparing valuation metrics of similar companies.Vivos Therapeutics is currently under evaluation in revenue category among its peers.
Vivos Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Vivos Therapeutics from analyzing Vivos Therapeutics' financial statements. These drivers represent accounts that assess Vivos Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vivos Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 111.6M | 107.6M | 9.3M | 15.2M | 21.5M | 20.5M | |
| Enterprise Value | 114.8M | 90.7M | 8.1M | 15.5M | 16.8M | 15.9M |
Vivos Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vivos Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vivos Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Vivos Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Vivos Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Vivos Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Vivos Therapeutics' value.| Shares | Signaturefd, Llc | 2025-03-31 | 547 | Group One Trading, Lp | 2025-03-31 | 228 | Advisor Group Holdings, Inc. | 2025-03-31 | 200 | Ronald Blue Trust, Inc. | 2025-03-31 | 160 | Bank Of America Corp | 2025-03-31 | 130 | Kozak & Associates, Inc. | 2025-03-31 | 49.0 | Global Retirement Partners, Llc. | 2024-12-31 | 23.0 | Steward Partners Investment Advisory, Llc | 2025-03-31 | 8.0 | Tower Research Capital Llc | 2025-03-31 | 0.0 | Geode Capital Management, Llc | 2025-03-31 | 57.3 K | Cutter & Co Brokerage, Inc. | 2025-03-31 | 49.1 K |
Vivos Fundamentals
| Return On Equity | -4.5 | ||||
| Return On Asset | -0.61 | ||||
| Profit Margin | (0.77) % | ||||
| Operating Margin | (1.30) % | ||||
| Current Valuation | 25.32 M | ||||
| Shares Outstanding | 5.89 M | ||||
| Shares Owned By Insiders | 32.99 % | ||||
| Shares Owned By Institutions | 9.08 % | ||||
| Number Of Shares Shorted | 310.37 K | ||||
| Price To Book | 5.96 X | ||||
| Price To Sales | 1.80 X | ||||
| Revenue | 15.03 M | ||||
| Gross Profit | 8.59 M | ||||
| EBITDA | (10.55 M) | ||||
| Net Income | (11.14 M) | ||||
| Cash And Equivalents | 17.83 M | ||||
| Cash Per Share | 0.77 X | ||||
| Total Debt | 1.51 M | ||||
| Debt To Equity | 0.10 % | ||||
| Current Ratio | 3.15 X | ||||
| Book Value Per Share | 0.75 X | ||||
| Cash Flow From Operations | (12.69 M) | ||||
| Short Ratio | 0.15 X | ||||
| Earnings Per Share | (1.04) X | ||||
| Target Price | 4.22 | ||||
| Number Of Employees | 113 | ||||
| Beta | 6.98 | ||||
| Market Capitalization | 26.27 M | ||||
| Total Asset | 15.28 M | ||||
| Retained Earnings | (104.19 M) | ||||
| Working Capital | 2.5 M | ||||
| Net Asset | 15.28 M |
About Vivos Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vivos Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vivos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vivos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vivos Stock Analysis
When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.